Rituximab in Membranous Nephropathy

Gauckler, Philipp and Shin, Jae Il and Alberici, Federico and Audard, Vincent and Bruchfeld, Annette and Busch, Martin and Cheung, Chee Kay and Crnogorac, Matija and Delbarba, Elisa and Eller, Kathrin and Faguer, Stanislas and Galesic, Kresimir and Griffin, Siân and van den Hoogen, Martijn W. F. and Hrušková, Zdenka and Jeyabalan, Anushya and Karras, Alexandre and King, Catherine and Singh Kohli, Harbir and Mayer, Gert and Maas, Rutger and Muto, Masahiro and Moiseev, Sergey and Odler, Balazs and Pepper, Ruth J. and Quintana, Luis F. and Radhakrishnan, Jai and Ramachandran, Raja and Salama, Alan D. and Schönermarck, Ulf and Segelmark, Mårten and Smith, Lee and Tesař, Vladimír and Wetzels, Jack and Willcocks, Lisa and Windpessl, Martin and Zand, Ladan and Zonozi, Reza and Kronbichler, Andreas (2021) Rituximab in Membranous Nephropathy. Kidney International Reports, 6 (4). pp. 881-893. ISSN 2468-0249

[img]
Preview
Text
Published Version
Available under the following license: Creative Commons Attribution Non-commercial No Derivatives.

Download (640kB) | Preview
[img] Text
Accepted Version
Restricted to Repository staff only
Available under the following license: Creative Commons Attribution Non-commercial No Derivatives.

Download (246kB) | Request a copy
Official URL: https://doi.org/10.1016/j.ekir.2020.12.035

Abstract

Membranous nephropathy is the most common cause of primary nephrotic syndrome among adults. The identification of phospholipase A2 receptor (PLA2R) as target antigen in a majority of patients changed the management of membranous nephropathy dramatically, and provided a rationale for B cell depleting agents such as rituximab. The efficacy of rituximab in inducing remission has been investigated in several studies including three randomized controlled trials, in which complete and partial remission of proteinuria was achieved in about two thirds of treated patients. Due to its favorable safety profile, rituximab is now considered a first-line treatment option for membranous nephropathy, especially in patients at moderate and high risk of deterioration in kidney function. However, questions remain about how to best use rituximab, including the optimal dosing regimen, a potential need for maintenance therapy and assessment of long-term safety and efficacy outcomes. In this review, we provide an overview of the current literature and discuss both strengths and limitations of “the new standard”.

Item Type: Journal Article
Keywords: Membranous nephropathy, nephrotic syndrome, rituximab, B Cells
Faculty: Faculty of Science & Engineering
SWORD Depositor: Symplectic User
Depositing User: Symplectic User
Date Deposited: 14 Jan 2021 16:45
Last Modified: 20 Apr 2021 12:41
URI: https://arro.anglia.ac.uk/id/eprint/706179

Actions (login required)

Edit Item Edit Item